drugset / Trial / NCT03241446
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
Non-randomizedSequentialOpen-labelDiagnostic
Summary
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
Timeline
- Start
- 2017-09
- Primary completion
- 2018-01
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilmanocept | Diagnostic / imaging agent | 50 ug | Intravenous |
| Subject | Tilmanocept | Diagnostic / imaging agent | 200 ug | Intravenous |
| Subject | Tilmanocept | Diagnostic / imaging agent | 400 ug | Intravenous |